Insulin resistance dysregulates CYP7B1 leading to oxysterol accumulation: a pathway for NAFL to NASH transition

NAFLD is an important public health issue closely associated with the pervasive epidemics of diabetes and obesity. Yet, despite NAFLD being among the most common of chronic liver diseases, the biological factors responsible for its transition from benign nonalcoholic fatty liver (NAFL) to NASH remain unclear. This lack of knowledge leads to a decreased ability to find relevant animal models, predict disease progression, or develop clinical treatments. In the current study, we used multiple mouse models of NAFLD, human correlation data, and selective gene overexpression of steroidogenic acute regulatory protein (StarD1) in mice to elucidate a plausible mechanistic pathway for promoting the transition from NAFL to NASH. We show that oxysterol 7α-hydroxylase (CYP7B1) controls the levels of intracellular regulatory oxysterols generated by the “acidic/alternative” pathway of cholesterol metabolism. Specifically, we report data showing that an inability to upregulate CYP7B1, in the setting of insulin resistance, results in the accumulation of toxic intracellular cholesterol metabolites that promote inflammation and hepatocyte injury. This metabolic pathway, initiated and exacerbated by insulin resistance, offers insight into approaches for the treatment of NAFLD.

[1]  J. Schaffer Death by lipids: The role of small nucleolar RNAs in metabolic stress , 2020, The Journal of Biological Chemistry.

[2]  A. Duseja,et al.  Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. , 2020, Journal of clinical and experimental hepatology.

[3]  Pradeep S B Podila,et al.  Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. , 2020, Journal of clinical and experimental hepatology.

[4]  Lanming Chen,et al.  High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation , 2020, iScience.

[5]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[6]  R. Andrade,et al.  Endoplasmic Reticulum Stress-induced Upregulation of STARD1 Promotes Acetaminophen-induced Acute Liver Failure. , 2019, Gastroenterology.

[7]  K. Cusi,et al.  Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease , 2019, Hepatology.

[8]  N. Mano,et al.  Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. , 2019, Toxicology and applied pharmacology.

[9]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[10]  W. Pandak,et al.  The acidic pathway of bile acid synthesis: Not just an alternative pathway , 2019, Liver research.

[11]  T. Hearn,et al.  Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis[S] , 2019, Journal of Lipid Research.

[12]  D. Conrad,et al.  A Disintegrin and Metalloproteinase 17 is required for ILC2 responses to IL-33. , 2019, Biochemical and biophysical research communications.

[13]  H. Nittono,et al.  Mitochondrial oxysterol biosynthetic pathway gives evidence for CYP7B1 as controller of regulatory oxysterols , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  E. Arenas,et al.  Mining for Oxysterols in Cyp7b1−/− Mouse Brain and Plasma: Relevance to Spastic Paraplegia Type 5 , 2019, Biomolecules.

[15]  E. Bugianesi,et al.  NASH in Lean Individuals , 2019, Seminars in Liver Disease.

[16]  H. Ha,et al.  Integrative Omics Reveals Metabolic and Transcriptomic Alteration of Nonalcoholic Fatty Liver Disease in Catalase Knockout Mice , 2019, Biomolecules & therapeutics.

[17]  G. Marchesini,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. , 2019, Transplantation.

[18]  C. Hetz,et al.  Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.

[19]  Y. Maor,et al.  Expression of the chemokine CCL24 and its receptor in the sera and livers of patients with non-alcoholic fatty liver disease , 2018 .

[20]  R. Thimme,et al.  Lost in Inflammation: The Functional Conversion of Regulatory T Cells in Acute Hepatitis A Virus Infection. , 2018, Gastroenterology.

[21]  A. Durr,et al.  Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5 , 2018, Brain : a journal of neurology.

[22]  M. Dotti,et al.  SPG5 siblings with different phenotypes showing reduction of 27-hydroxycholesterol after simvastatin-ezetimibe treatment , 2017, Journal of the Neurological Sciences.

[23]  Shimona Starling Type 2 immunity: Hero turns villain in fatty liver , 2017, Nature Reviews Immunology.

[24]  T. Wynn,et al.  Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β , 2017, Science Translational Medicine.

[25]  A. Moffett NK cell allorecognition , 2017, Nature Reviews Immunology.

[26]  Britta Noebauer,et al.  Hepatic Cholesterol-25-Hydroxylase Overexpression Improves Systemic Insulin Sensitivity in Mice , 2017, Journal of diabetes research.

[27]  Tongzhi Wu,et al.  Bile acid profiles in diabetic (db/db) mice and their wild type littermates. , 2016, Journal of pharmaceutical and biomedical analysis.

[28]  Y. Iwakiri Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase , 2015, Clinical and molecular hepatology.

[29]  A. Sanyal,et al.  Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.

[30]  D. Ory,et al.  A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid[S] , 2015, Journal of Lipid Research.

[31]  Robert J. Smith,et al.  Fatty liver disease in diabetes mellitus. , 2015, Hepatobiliary surgery and nutrition.

[32]  Anita C. Thomas,et al.  “Of Mice and Men”: Arginine Metabolism in Macrophages , 2014, Front. Immunol..

[33]  D. Russell,et al.  25-Hydroxycholesterol suppresses interleukin-1–driven inflammation downstream of type I interferon , 2014, Science.

[34]  E. Gold,et al.  25-Hydroxycholesterol acts as an amplifier of inflammatory signaling , 2014, Proceedings of the National Academy of Sciences.

[35]  C. Mineo,et al.  The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. , 2014, Cell metabolism.

[36]  H. Nittono,et al.  A simple and accurate HPLC method for fecal bile acid profile in healthy and cirrhotic subjects: validation by GC-MS and LC-MS[S] , 2014, Journal of Lipid Research.

[37]  H. Nittono,et al.  Liver disease in infancy caused by oxysterol 7α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid , 2014, Journal of Inherited Metabolic Disease.

[38]  F. Ginanneschi,et al.  Hereditary spastic paraplegia type 5: a potentially treatable disorder of cholesterol metabolism , 2014, Journal of Neurology.

[39]  U. Diczfalusy On the formation and possible biological role of 25-hydroxycholesterol. , 2013, Biochimie.

[40]  Kenji Suzuki,et al.  A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma , 2013, Medical Molecular Morphology.

[41]  G. Cheng,et al.  Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. , 2013, Immunity.

[42]  Kevin A. Robertson,et al.  The Transcription Factor STAT-1 Couples Macrophage Synthesis of 25-Hydroxycholesterol to the Interferon Antiviral Response , 2013, Immunity.

[43]  H. Rakugi,et al.  Analysis of hepatic gene expression profile in a spontaneous mouse model of type 2 diabetes under a high sucrose diet. , 2013, Endocrine journal.

[44]  J. Gustafsson,et al.  Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. , 2012, Immunity.

[45]  M. Ichinose,et al.  25-hydroxycholesterol enhances cytokine release and toll-like receptor 3 response in airway epithelial cells , 2012, Respiratory Research.

[46]  P. Hylemon,et al.  25-Hydroxycholesterol-3-sulfate attenuates inflammatory response via PPARγ signaling in human THP-1 macrophages. , 2012, American journal of physiology. Endocrinology and metabolism.

[47]  D. Rozman,et al.  Review Article Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation , 2022 .

[48]  A. Harada,et al.  Induction of Liver Steatosis and Lipid Droplet Formation in ATF6α-Knockout Mice Burdened with Pharmacological Endoplasmic Reticulum Stress , 2010, Molecular biology of the cell.

[49]  N. Siddique,et al.  Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis , 2010, Journal of Lipid Research.

[50]  Xiaobo Li,et al.  Overexpression of mitochondrial cholesterol delivery protein, StAR, decreases intracellular lipids and inflammatory factors secretion in macrophages. , 2009, Atherosclerosis.

[51]  A. Smith,et al.  Arginase-1–Expressing Macrophages Suppress Th2 Cytokine–Driven Inflammation and Fibrosis , 2009, PLoS pathogens.

[52]  M. Katze,et al.  UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. , 2008, Developmental cell.

[53]  Wanjin Tang,et al.  Involvement of the PI3K/Akt pathway in estrogen-mediated regulation of human CYP7B1: Identification of CYP7B1 as a novel target for PI3K/Akt and MAPK signalling , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[54]  C. Kahn,et al.  Hepatic insulin resistance directly promotes formation of cholesterol gallstones , 2008, Nature Medicine.

[55]  N. Tajima,et al.  Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats , 2006, Diabetologia.

[56]  C. Bona,et al.  B cells: no longer bystanders in liver fibrosis. , 2005, The Journal of clinical investigation.

[57]  P. Hylemon,et al.  Overexpression of cholesterol transporter StAR increases In Vivo rates of bile acid synthesis in the rat and mouse , 2004, Hepatology.

[58]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[59]  P. Hylemon,et al.  Regulation of oxysterol 7α‐hydroxylase (CYP7B1) in primary cultures of rat hepatocytes , 2002 .

[60]  N. Javitt 25R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. , 2002, Journal of lipid research.

[61]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[62]  R. Fisher,et al.  Effects of CYP7A1 overexpression on cholesterol and bile acid homeostasis. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[63]  P. Hylemon,et al.  Expression of sterol 12alpha-hydroxylase alters bile acid pool composition in primary rat hepatocytes and in vivo. , 2001, Gastroenterology.

[64]  D. Russell,et al.  Disruption of the Oxysterol 7α-Hydroxylase Gene in Mice* , 2000, The Journal of Biological Chemistry.

[65]  Zhengliang L. Wu,et al.  Structure and functions of human oxysterol 7alpha-hydroxylase cDNAs and gene CYP7B1. , 1999, Journal of lipid research.

[66]  T. Osborne,et al.  Oxysterol Regulation of Steroidogenic Acute Regulatory Protein Gene Expression , 1998, The Journal of Biological Chemistry.

[67]  R. Arnon,et al.  Cholesterol 7-hydroxylase knockout mouse: a model for monohydroxy bile acid-related neonatal cholestasis. , 1998, Gastroenterology.

[68]  R. Lathe,et al.  Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. , 1998, The Journal of clinical investigation.

[69]  J. Litz,et al.  Hormonal regulation of cholesterol 7 alpha-hydroxylase mRNA levels and transcriptional activity in primary rat hepatocyte cultures. , 1992, The Journal of biological chemistry.

[70]  G. Schonfeld,et al.  Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. , 1990, Metabolism: clinical and experimental.